Anavex Life Sciences Corp (AVXL)
3.90
+0.01
(+0.26%)
USD |
NASDAQ |
May 10, 10:56
Anavex Life Sciences Cash from Financing (TTM): 29.45M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 29.45M |
September 30, 2023 | 29.65M |
June 30, 2023 | 27.60M |
March 31, 2023 | 25.50M |
December 31, 2022 | 19.01M |
September 30, 2022 | 21.29M |
June 30, 2022 | 23.51M |
March 31, 2022 | 105.82M |
December 31, 2021 | 129.80M |
September 30, 2021 | 153.24M |
June 30, 2021 | 158.90M |
March 31, 2021 | 74.78M |
December 31, 2020 | 43.33M |
September 30, 2020 | 28.35M |
June 30, 2020 | 23.94M |
March 31, 2020 | 28.13M |
December 31, 2019 | 26.84M |
September 30, 2019 | 17.78M |
June 30, 2019 | 15.47M |
March 31, 2019 | 8.434M |
December 31, 2018 | 5.789M |
September 30, 2018 | 8.073M |
June 30, 2018 | 11.76M |
March 31, 2018 | 13.91M |
December 31, 2017 | 16.37M |
Date | Value |
---|---|
September 30, 2017 | 27.27M |
June 30, 2017 | 23.76M |
March 31, 2017 | 19.34M |
December 31, 2016 | 16.45M |
September 30, 2016 | 3.133M |
June 30, 2016 | 10.57M |
March 31, 2016 | 13.65M |
December 31, 2015 | 13.65M |
September 30, 2015 | 12.26M |
June 30, 2015 | 3.493M |
March 31, 2015 | 0.358M |
December 31, 2014 | 9.803M |
September 30, 2014 | 9.580M |
June 30, 2014 | 10.41M |
March 31, 2014 | 10.49M |
December 31, 2013 | 1.100M |
September 30, 2013 | 1.111M |
June 30, 2013 | 0.5284M |
March 31, 2013 | 0.5734M |
December 31, 2012 | 0.8071M |
September 30, 2012 | 1.570M |
June 30, 2012 | 1.159M |
March 31, 2012 | 3.506M |
December 31, 2011 | 3.391M |
September 30, 2011 | 3.672M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
15.47M
Minimum
Jun 2019
158.90M
Maximum
Jun 2021
51.70M
Average
28.13M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
Ventyx Biosciences Inc | 53.33M |
Checkpoint Therapeutics Inc | 40.45M |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |